Highlight
- LB-102 (N-methyl amisulpride) showed statistically significant improvement over placebo in reducing psychotic symptoms in adults with acute schizophrenia.
- The 28-day phase 2 NOVA1 trial demonstrated meaningful reductions in PANSS total scores at both 50 mg and 75 mg doses, with an acceptable safety profile.
- Higher doses (100 mg) of LB-102 showed nominal significance but were associated with increased adverse events, warranting cautious dose optimization.
Study Background
Schizophrenia is a complex psychiatric disorder characterized by psychotic symptoms such as hallucinations, delusions, and cognitive dysfunction. Acute exacerbations often require hospitalization and urgent management. Although many antipsychotics are currently available, gaps remain in optimizing efficacy, tolerability, and safety profiles, especially for new benzamide derivatives. LB-102, a novel benzamide structurally related to amisulpride, targets dopamine D2/D3 receptors with preferential limbic selectivity, potentially offering improved symptom control with reduced extrapyramidal side effects.
Study Design
The NOVA1 study was a randomized, double-blind, placebo-controlled, phase 2 clinical trial conducted at multiple US centers between December 2023 and August 2024. Eligible participants were adults 18–55 years hospitalized or requiring hospitalization for acute schizophrenia exacerbation, with stringent inclusion criteria emphasizing moderate-to-severe symptom burden (PANSS total score 80–120; ≥4 rating on two or more Positive Symptoms subscale items; CGI-S score ≥4).
Participants were randomized in a 3:3:3:1 ratio to receive daily oral doses of LB-102 at 50 mg, 75 mg, 100 mg, or placebo over a 28-day inpatient treatment period. The protocol included a screening phase (up to 14 days), a five-day inpatient stabilization period following treatment, and a two-week outpatient safety follow-up.
The primary endpoint was the change from baseline to week 4 in PANSS total score, analyzed using Hochberg multiplicity correction for the 50 mg and 75 mg doses versus placebo. Secondary endpoints involved changes in Clinical Global Impressions-Severity (CGI-S) score, CGIS response rates, PANSS subscale and Marder factor scores, and responder rates defined by ≥20% improvement in PANSS.
Safety assessments included treatment-emergent adverse events (TEAEs), serious adverse events, withdrawals due to adverse events, and vital signs monitoring.
Key Findings
The study enrolled 359 participants with a balanced demographic distribution (mean age 39.1 years; 80.8% male). Baseline symptom severity was comparable across groups (mean PANSS total ~94).
Both LB-102 50 mg and 75 mg groups achieved statistically significant reductions in PANSS total scores compared to placebo at week 4 (mean changes: 50 mg, -14.3; 75 mg, -14.0; placebo, -9.3; with P<.001 and P=.002 respectively). Effect sizes (Hedges g) indicated moderate clinical effects (0.61 for 50 mg, 0.41 for 75 mg). The 100 mg dose demonstrated the largest numeric improvement (-16.1) with a nominal P value of .002 and a large effect size (0.83), though multiplicity correction was not reported for this dose cohort due to smaller participant numbers (n=36).
Secondary end point analyses paralleled primary outcomes, showing improvements in CGI-S scores and responder rates, supporting consistent symptomatic benefit.
Safety data revealed higher TEAE rates among LB-102 recipients (50 mg, 69%; 75 mg, 57%; 100 mg, 75%) relative to placebo (56%). Common TEAEs were generally mild to moderate, although ten participants withdrew due to adverse events, evenly distributed across groups. Five serious adverse events were reported, including one death in the placebo group and one serious event per LB-102 dose group. No new safety signals were identified.
Expert Commentary
This trial provides robust clinical evidence supporting the efficacy of LB-102 as a promising benzamide antipsychotic for acute schizophrenia. The moderate to large effect sizes for PANSS reduction at the 50 mg and 75 mg doses are clinically meaningful and align with improvements needed to alleviate acute psychotic episodes.
Safety and tolerability appear acceptable for clinical practice, although the increased adverse event frequency at the highest dose suggests careful attention to dose titration is warranted. The trial’s inpatient design and stringent patient selection enhance internal validity but may limit generalizability to less acute or outpatient populations.
Mechanistically, LB-102’s selective dopaminergic receptor modulation may confer a favorable balance between antipsychotic efficacy and side effect burden, consistent with the pharmacodynamic profile of benzamide agents. Further phase 3 studies with larger cohorts and longer durations are necessary to confirm durability of benefits and long-term safety.
Conclusion
The NOVA1 randomized clinical trial establishes LB-102 as an effective and generally well-tolerated treatment for adults with acute schizophrenia. Given the burden of psychotic exacerbations and the need for novel treatments that improve symptoms without compromising safety, LB-102 represents an important advancement in the psychopharmacology landscape. Future research should validate these findings in diverse populations and explore the drug’s use in maintenance therapy.
Funding and Clinical Trial Registration
This trial was registered at ClinicalTrials.gov under Identifier: NCT06179108. Funding sources were not specified in the abstract publication.
References
- Eramo A, Correll CU, Walling DP, et al. Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adults With Acute Schizophrenia: A Randomized Clinical Trial. JAMA Psychiatry. 2026;83(7):682-693. PMID: 42018313.
- Kane JM, Correll CU. Past and Present Progress in the Pharmacologic Treatment of Schizophrenia. J Clin Psychiatry. 2010;71(9):1115-1124.
- Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry. 2009;14(4):429-447.
